Our vision is to transform humankind through fusion technology and its vast potential to create a safer, healthier, cleaner world.
Rather than just talk about what we’ll do someday, we deliver measurable results every week. That’s because we run revenue-generating fusion systems right now that provide vital products and services to paying customers.
Our market-first approach lets us reinvest in our capabilities and continue to improve. That’s how we plan to achieve our ultimate goal: to produce clean, abundant fusion energy at scale.
Our progress in fusion is documented, regulated, and repeatable.
Our technology operates reliably, scales safely, and has gained regulatory confidence in real markets:
Founder and CEO Greg Piefer leads a team that includes physicists, nuclear engineers, radiochemists, and seasoned strategists from the nuclear, medical, and manufacturing worlds. They’ve turned fusion from a research goal into a working business—one that operates under NRC oversight and to current Good Manufacturing Practice standards.
We put integrity, safety, and accountability at the center of everything we do. And we’re proving that fusion can be developed, operated, and continually improved upon—just like other breakthrough technologies.
.png)
The credibility of our work is reflected in the company we keep. We collaborate with leading agencies, laboratories, and innovators that share our drive to prove what fusion can do.
Our partners include the U.S. Department of Energy’s Advanced Research Projects Agency–Energy (ARPA-E), Argonne National Laboratory, the University of Wisconsin–Madison, Orano, the UK Atomic Energy Authority, Deep Isolation, Zeno Power, and many others.
These collaborations extend SHINE’s fusion technology into national research efforts and global industrial applications.
Our 105-acre headquarters includes Chrysalis, Cassiopeia, and Building One. Chrysalis, under construction, will supply molybdenum-99 for medical imaging. Cassiopeia, our lutetium-177 facility, can meet rising demand for cancer therapies. Building One supports ongoing technology development, including FLARE.
Our Fitchburg campus, Heliopolis, houses our Systems and Manufacturing division, where fusion systems are designed, built, and tested. The same site includes the Phoenix Imaging Center, which provides neutron radiography and testing for aerospace, defense, and advanced manufacturing.
Our Fitchburg campus, Heliopolis, houses our Systems and Manufacturing division, where fusion systems are designed, built, and tested. The same site includes the Phoenix Imaging Center, which provides neutron radiography and testing for aerospace, defense, and advanced manufacturing.
SHINE Europe is developing the company’s first medical-isotope production facility outside the U.S. The planned site will follow the Chrysalis design to provide molybdenum-99 and lutetium-177 for European clinics and research partners, helping strengthen resilience in the global isotope supply chain.
